261 related articles for article (PubMed ID: 33470084)
1. Do catastrophic costs impact treatment outcomes in people with rifampicin-resistant tuberculosis in the Republic of Moldova?
Plesca V; Ciobanu A; Sereda Y; Dadu A
Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470084
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015.
Matambo R; Takarinda KC; Thekkur P; Sandy C; Mharakurwa S; Makoni T; Ncube R; Charambira K; Zishiri C; Ngwenya M; Nyathi S; Chiteka A; Chikaka E; Mutero-Munyati S
PLoS One; 2020; 15(4):e0230848. PubMed ID: 32353043
[TBL] [Abstract][Full Text] [Related]
3. Defining catastrophic costs and comparing their importance for adverse tuberculosis outcome with multi-drug resistance: a prospective cohort study, Peru.
Wingfield T; Boccia D; Tovar M; Gavino A; Zevallos K; Montoya R; Lönnroth K; Evans CA
PLoS Med; 2014 Jul; 11(7):e1001675. PubMed ID: 25025331
[TBL] [Abstract][Full Text] [Related]
4. Determinants of catastrophic costs among households affected by multi-drug resistant tuberculosis in Ho Chi Minh City, Viet Nam: a prospective cohort study.
Pham TAM; Forse R; Codlin AJ; Phan THY; Nguyen TT; Nguyen N; Vo LNQ; Dat PT; Minh HDT; Nguyen LH; Nguyen HB; Nguyen NV; Bodfish M; Lönnroth K; Wingfield T; Annerstedt KS
BMC Public Health; 2023 Dec; 23(1):2372. PubMed ID: 38042797
[TBL] [Abstract][Full Text] [Related]
5. Catastrophic total costs in tuberculosis-affected households and their determinants since Indonesia's implementation of universal health coverage.
Fuady A; Houweling TAJ; Mansyur M; Richardus JH
Infect Dis Poverty; 2018 Jan; 7(1):3. PubMed ID: 29325589
[TBL] [Abstract][Full Text] [Related]
6. Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysis.
Akalu TY; Clements ACA; Wolde HF; Alene KA
Sci Rep; 2023 Dec; 13(1):22361. PubMed ID: 38102144
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with unfavourable treatment outcomes among people with rifampicin-resistant tuberculosis in Armenia, 2014-2017.
Khachatryan L; Grigoryan R; Dadu A; Kumar AMV; Akopyan K; Dumchev K; Harutyunyan H; Matteelli A
Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470086
[TBL] [Abstract][Full Text] [Related]
8. Incidence and factors associated with unfavourable treatment outcome among patients with rifampicin-resistant pulmonary tuberculosis in Yaoundé, Cameroon.
Kuaban A; Balkissou AD; Ekongolo MCE; Nsounfon AW; Pefura-Yone EW; Kuaban C
Pan Afr Med J; 2021; 38():229. PubMed ID: 34046134
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment outcomes in patients with multidrug-resistant tuberculosis.
Maier C; Chesov D; Schaub D; Kalsdorf B; Andres S; Friesen I; Reimann M; Lange C
Clin Microbiol Infect; 2023 Jun; 29(6):751-757. PubMed ID: 36842637
[TBL] [Abstract][Full Text] [Related]
10. Beyond pills and tests: addressing the social determinants of tuberculosis.
Wingfield T; Tovar MA; Huff D; Boccia D; Saunders MJ; Datta S; Montoya R; Ramos E; Lewis JJ; Gilman RH; Evans C
Clin Med (Lond); 2016 Dec; 16(Suppl 6):s79-s91. PubMed ID: 27956446
[TBL] [Abstract][Full Text] [Related]
11. High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.
Naz F; Ahmad N; Wahid A; Ahmad I; Khan A; Abubakar M; Khan SA; Khan A; Latif A; Ghafoor A
BMC Infect Dis; 2021 Dec; 21(1):1209. PubMed ID: 34863099
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with unfavorable treatment outcomes in patients with rifampicin-resistant tuberculosis in Colombia 2013-2015: A retrospective cohort study.
Chaves-Torres NM; Fadul S; Patiño J; Netto E
PLoS One; 2021; 16(4):e0249565. PubMed ID: 33852619
[TBL] [Abstract][Full Text] [Related]
13. Catastrophic costs incurred by tuberculosis affected households from Thailand's first national tuberculosis patient cost survey.
Youngkong S; Kamolwat P; Wongrot P; Thavorncharoensap M; Chaikledkaew U; Nateniyom S; Pungrassami P; Praditsitthikorn N; Mahasirimongkol S; Jittikoon J; Nishikiori N; Baena IG; Yamanaka T
Sci Rep; 2024 May; 14(1):11205. PubMed ID: 38755216
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan.
Makhmudova M; Maxsumova Z; Rajabzoda A; Makhmadov A; van den Hof S; Mirtskhulava V
Int J Tuberc Lung Dis; 2019 Mar; 23(3):331-336. PubMed ID: 30871664
[TBL] [Abstract][Full Text] [Related]
15. Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study.
Chen B; Chen X; Ren Y; Peng Y; Wang F; Zhou L; Xu B
J Infect Public Health; 2023 Jul; 16(7):1073-1080. PubMed ID: 37209611
[TBL] [Abstract][Full Text] [Related]
16. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
[TBL] [Abstract][Full Text] [Related]
18. The economic burden of households affected by tuberculosis in Brazil: First national survey results, 2019-2021.
Noia Maciel EL; Negri LDSA; Guidoni LM; Fregona GC; Johansen FDC; Sanchez MN; Moreira ADSR; Diaz-Quijano FA; Tonini M; Zandonade E; Ershova J; Nguhiu P; Baena IG
PLoS One; 2023; 18(12):e0287961. PubMed ID: 38091306
[TBL] [Abstract][Full Text] [Related]
19. Effect of financial support on reducing the incidence of catastrophic costs among tuberculosis-affected households in Indonesia: eight simulated scenarios.
Fuady A; Houweling TAJ; Mansyur M; Burhan E; Richardus JH
Infect Dis Poverty; 2019 Feb; 8(1):10. PubMed ID: 30709415
[TBL] [Abstract][Full Text] [Related]
20. The socioeconomic impact of multidrug resistant tuberculosis on patients: results from Ethiopia, Indonesia and Kazakhstan.
van den Hof S; Collins D; Hafidz F; Beyene D; Tursynbayeva A; Tiemersma E
BMC Infect Dis; 2016 Sep; 16(1):470. PubMed ID: 27595779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
